Literature DB >> 21115164

Pheochromocytomas: the (pseudo)-hypoxia hypothesis.

Judith Favier1, Anne-Paule Gimenez-Roqueplo.   

Abstract

Hypoxia and pheochromocytoma/paraganglioma have a long common history. Since the description, almost 40 years ago, of an increased incidence of head and neck paragangliomas in chronic hypoxia, discoveries on oxygen-sensing and on hereditary paraganglioma in the beginning of years 2000 provided the proof of concept of a strong link between these neuroendocrine tumors and the hypoxic pathway. It was demonstrated that both SDH and VHL genes mutations lead to the abnormal stabilization and activation of hypoxia-inducible factors, and to the subsequent regulation of multiple target genes, the products of which are implicated in proliferation, apoptosis, angiogenesis, energy metabolism or invasiveness and metastases. Altogether, physiological, genetic, cellular and molecular data collected over years all point to a central role of the hypoxic or pseudohypoxic pathway in pheochromocytoma and paraganglioma tumorigenesis. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115164     DOI: 10.1016/j.beem.2010.10.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  44 in total

Review 1.  An update on the genetics of pheochromocytoma.

Authors:  D Karasek; U Shah; Z Frysak; C Stratakis; K Pacak
Journal:  J Hum Hypertens       Date:  2012-05-31       Impact factor: 3.012

2.  The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators.

Authors:  Guillaume Gravel; Patricia Niccoli; Vincent Rohmer; Guy Moulin; Françoise Borson-Chazot; Pascal Rousset; Anne Pasco-Papon; Claude Marcus; Frédérique Dubrulle; Hervé Gouya; François Bidault; Benoit Dupas; Jean Gabrillargues; Aurore Caumont-Prim; Anne Hernigou; Anne-Paule Gimenez-Roqueplo; Philippe Halimi
Journal:  Eur Radiol       Date:  2015-10-01       Impact factor: 5.315

Review 3.  Pheochromocytoma: The First Metabolic Endocrine Cancer.

Authors:  Ivana Jochmanova; Karel Pacak
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

Review 4.  Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.

Authors:  Ales Vicha; David Taieb; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2014-05-08       Impact factor: 5.678

Review 5.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

6.  Pheochromocytoma and paraganglioma in cyanotic congenital heart disease.

Authors:  Alexander R Opotowsky; Lilamarie E Moko; Jonathan Ginns; Marlon Rosenbaum; Matthias Greutmann; Jamil Aboulhosn; Abbie Hageman; Yuli Kim; Lisa X Deng; Jasmine Grewal; Ali N Zaidi; Ghadeera Almansoori; Erwin Oechslin; Michael Earing; Michael J Landzberg; Michael N Singh; Fred Wu; Anand Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2015-01-12       Impact factor: 5.958

7.  Phaeochromocytoma: a catecholamine and oxidative stress disorder.

Authors:  K Pacak
Journal:  Endocr Regul       Date:  2011-04

Review 8.  Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.

Authors:  P Björklund; K Pacak; J Crona
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 9.  Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.

Authors:  Svenja Nölting; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

Review 10.  Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.

Authors:  Ales Vicha; Zdenek Musil; Karel Pacak
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-06       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.